A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
New obesity drug with a novel mechanism of action will likely be much safer than stimulant alternatives which carry a high potential for cardiovascular events and abuse. This drug, which is not a controlled substance, stands to make this company a lot of money considering the obesity/diabetes epidemic in this country. Given this, I also anticipate eventual coverage by most major third party payers which will in turn increase the number of prescriptions for Belviq (lorcaserin)